High-Throughput
Mass Spec.
Unleashed.

High‑throughput mass spectrometry (HT‑MS) has evolved beyond simply increased sample speed - it is now the analytical core of next‑generation drug discovery. Every screen generates thousands of molecules along with thousands of corresponding data points. Managing terabytes of complex, multidimensional data requires a purpose‑built digital ecosystem that can scale with your science.

This is where Genedata comes in.

Genedata is invaluable for our ability to process the amount and especially the size of data files generated in HT-MS screening. I cannot quantify the improvement - either we were doing it with Genedata or not doing it at all.

Patrick Shelton
Principal Scientist

High-Throughput.
End-to-End.

Import raw data from all major MS instruments and combine it with metadata from compound registration and other systems to automatically parameterize MS analysis for each sample in the screen. Discover how the Genedata Biopharma Platform drives automation and facilitates efficient data analysis and reporting of peptide mapping results back to the central data backbone, with unique new enhancements that enable high-throughput screening and the creation of large, structured databases for downstream Machine Learning/Artificial Intelligence (ML/AI) applications.

HT-MS Analytics for ML/AI-Ready Drug Discovery

Multiplexed MS.
Accelerated Timelines.

Learn how Pfizer and Genedata partnered in the development of a fast and robust HT-MS assay that accelerates covalent ligand discovery in biopharmaceutical R&D. By integrating the Agilent RapidFire (RF) system with a quadrupole time-of-flight (QTOF) mass spectrometer and the Genedata Biopharma Platform, Pfizer established a robust workflow for rapid and multiplexed detection of covalent interactions between small-molecule inhibitors and target proteins.

A Multiplexed Platform for Covalent Ligand Screening

All MS Assays.
Comprehensive Coverage.

Intact Mass. Covalent Binding. Affinity Selection Mass Spectrometry (AS-MS). HT Peptide Mapping – and more. The Genedata Biopharma Platform covers all MS-based HT-MS screens and assays, enabling you to simplify data analysis, enhance quality assurance, and overcome bottlenecks. Learn how Sanofi is transforming early-stage drug discovery by integrating high-throughput chemical liability screening into its antibody development workflows. This innovative approach boosts screening throughput by up to 100-fold, enabling earlier identification of candidates with favorable developability profiles.

Chemical Liability Screening for Biotherapeutic Protein Discovery

Assay-Level Visualizations.
Biological-Level Insights.

Out-of-the-box, Genedata offers data visualizations at multiple levels — assays, plates, wells, spectra, and compounds — enabling at a glance data interpretation and seamless integration of MS-based assays with industry-standard screening quality control and analysis practices. Fully automate HT-MS spectral processing, data analysis, quality control, and reporting, enabling you to focus on the biological impact of your screens.

Affinity Selection-Driven Hit Filtering with Robust QC

100-fold screening throughput increase enables better quality of biologics, and faster time to clinic (up to 6 months). Another great benefit is to leverage ML for AI-based drug discovery.